S. Leshchenko

Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.

Arun K. Ghosh, I. Weber, R. Harrison, 2006, Journal of medicinal chemistry.

Stereoselective photochemical 1,3-dioxolane addition to 5-alkoxymethyl-2(5H)-furanone: synthesis of bis-tetrahydrofuranyl ligand for HIV protease inhibitor UIC-94017 (TMC-114).

Arun K. Ghosh, S. Leshchenko, Marcus W. Noetzel, 2004, The Journal of organic chemistry.

Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.

Arun K. Ghosh, D. Walters, H. Mitsuya, 2005, Journal of medicinal chemistry.

Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P′2-ligands

Arun K. Ghosh, D. Walters, H. Mitsuya, 2006 .

Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.

Arun K. Ghosh, J. Wedekind, I. Weber, 2006, Journal of medicinal chemistry.

Susceptibility of Potent Antiviral Inhibitor to Highly Drug Resistant Mutations D30N, I50V and L90M of HIV-1 Protease

R. Harrison, A. Kovalevsky, Y. Tie, 2011 .

Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114.

Irene T Weber, Robert W Harrison, Arun K. Ghosh, 2006, Journal of molecular biology.

High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains.

Irene T Weber, Robert W Harrison, Yuan-Fang Wang, 2004, Journal of molecular biology.